Boston Scientific is trading 4% down at $47.11 as investors react to recently lowered guidance and subsequent analyst estimate cuts.
- A fresh Zacks Bear of the Day note on August 5 highlighted reduced EPS forecasts following the July 29 earnings call.
- The report reinforces cautious sentiment and pressure on the stock despite solid underlying performance in the medtech business.